Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Thursday,Benzinga reports. The firm currently has a $80.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on CLDX. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup initiated coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 price target for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $25.14 on Thursday. The company has a market capitalization of $1.67 billion, a P/E ratio of -9.78 and a beta of 1.57. Celldex Therapeutics has a fifty-two week low of $22.93 and a fifty-two week high of $53.18. The stock has a 50-day simple moving average of $26.79 and a 200-day simple moving average of $33.36.

Insiders Place Their Bets

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its stake in shares of Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after acquiring an additional 325 shares in the last quarter. KBC Group NV boosted its position in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 1,504 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics during the 2nd quarter worth $76,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.